Syn2Bio

Syn2Bio S.A. Anticipates Interim Analysis Results for Phase III Cardiotracer Study in Q4 2026

Syn2Bio S.A. has announced that the Phase III clinical trials for its innovative cardiotracer, SYN2, are progressing on schedule across European centers. The company expects to receive interim analysis results in the fourth quarter of 2026. The cardiotracer, a radiopharmaceutical designed for heart disease diagnosis using PET/CT imaging, is being tested on a projected cohort of 200–220 patients, with final numbers to be confirmed after interim evaluations.

Patient recruitment in European centers has reached a level sufficient for the planned interim analysis. Meanwhile, preparations are underway in the United States to initiate clinical sites, including technology transfer for SYN2 production and quality assurance procedures. Patient recruitment in the U.S. is contingent on the FDA assigning an IND (Investigational New Drug) number.

Syn2Bio reported that its primary expenditures in Q2 2026, totaling approximately PLN 11 million, were allocated to intensified research and development activities. As of June 30, 2026, the company held cash reserves of nearly PLN 19 million, sufficient to fund research for an estimated 10–11 months. Additional funding may be sought through grants, subsidies, and development support programs targeted at small and medium-sized enterprises (SMEs), a status that Syn2Bio holds.

Syn2Bio reiterated that it does not anticipate generating revenue until the commercialization of SYN2, in line with its business model.

Relevance to Syn2Bio S.A.: This update highlights Syn2Bio's progress in advancing its flagship cardiotracer project, a core component of its business strategy, and underscores its financial planning and resource allocation to support ongoing clinical trials and eventual commercialization.

Syn2Bio S.A. Implements Key Corporate Decisions at Extraordinary General Meeting

On May 19, 2026, Syn2Bio S.A., a Warsaw-based innovator in radiopharmaceuticals for heart disease diagnostics, held an Extraordinary General Meeting of Shareholders to address critical corporate matters. The meeting resulted in the adoption of several resolutions aimed at enhancing the company's governance, financial structure, and operational policies.

• Appointment of Meeting Chairman: Wiesław Łatała was elected as the Chairman of the General Meeting, with unanimous approval from shareholders representing 47.31% of the company’s share capital.
• Approval of Agenda: The meeting approved the proposed agenda, which included key decisions on share buybacks, capital reduction, and governance policies.
• Share Buyback and Capital Reduction: The shareholders approved the voluntary buyback and cancellation of 200,000 Series A shares, representing 2.29% of the company’s share capital. This move reduced the company’s share capital from PLN 4,364,564.50 to PLN 4,264,564.50.
• Adoption of Remuneration Policy: A new remuneration policy was introduced to align executive and supervisory board compensation with the company’s long-term strategic goals and financial performance.
• Approval of Supervisory Board Regulations: The meeting adopted a comprehensive set of regulations for the Supervisory Board, detailing its responsibilities, meeting procedures, and conflict-of-interest policies.
• Supervisory Board Compensation: The shareholders approved monthly compensation for the Supervisory Board members, with the Chairman and Vice-Chairman receiving PLN 1,500 and other members receiving PLN 1,000. Additional compensation of PLN 500 was approved for members serving on committees.

All resolutions were passed with significant shareholder support, reflecting a strong consensus on the company’s strategic direction.

Relevance to Syn2Bio S.A.: These decisions are pivotal for strengthening Syn2Bio’s corporate governance and financial structure, ensuring the company is well-positioned to advance its phase-three clinical trials for its innovative cardiotracer and prepare for its commercialization phase.

Syn2Bio S.A. Gains Independence Following Strategic Spin-Off from Synektik S.A.

Syn2Bio S.A., a Polish company specializing in innovative radiopharmaceuticals for heart disease diagnosis, has officially been spun off from Synektik S.A. as part of a strategic restructuring. The spin-off, finalized on April 16, 2026, involved the transfer of assets valued at approximately PLN 43 million to Syn2Bio S.A., which now operates as an independent entity. The transaction resulted in a non-cash dividend payout to Synektik S.A. shareholders, who received Syn2Bio S.A. shares on a 1:1 basis.

The financial impact of the spin-off included a reported gain of PLN 261 million, calculated based on the fair market value of Syn2Bio S.A. shares on their first trading day on the Warsaw Stock Exchange. However, Synektik S.A.’s equity was reduced by PLN 304 million due to the transfer of assets, leading to a net equity decrease of PLN 43 million. These figures will be confirmed in Synektik S.A.’s interim financial report for the period ending March 31, 2026, subject to auditor review.

Syn2Bio S.A. is now positioned to independently advance its flagship cardiotracer project, which is in phase-three clinical trials, and pursue commercialization opportunities. The company also oversees the Centre for Research on New Compounds, focusing on the development and market launch of innovative pharmaceutical products.

Relevance: This article highlights Syn2Bio S.A.’s transition to an independent entity, enabling it to focus exclusively on its cardiotracer project and pharmaceutical research, aligning with its business profile and strategic goals.

Syn2Bio S.A. Board Member's Close Associate Acquires Company Shares

On April 20, 2026, Syn2Bio S.A. announced a transaction involving the acquisition of 2,300 company shares by Mr. Maciej Zarębiński, a close associate of Ms. Sawa Zarębińska, a member of the Supervisory Board. The shares were purchased at a price of 34 PLN per share on April 16, 2026, through the Warsaw Stock Exchange (XWAR). The transaction was disclosed in compliance with Article 19(1) of the MAR Regulation, and the full notification is available in the company's official report.

This development highlights the confidence of individuals closely associated with Syn2Bio's leadership in the company's future prospects, particularly as it advances its innovative cardiotracer radiopharmaceutical through phase-three clinical trials and continues its efforts in pharmaceutical research and commercialization.

Insider Transaction Reported at Syn2Bio S.A. Involving Board Member's Close Associate

On April 20, 2026, Syn2Bio S.A. announced a transaction involving the acquisition of company shares by Ms. Zuzanna Zarębińska, a close associate of Ms. Sawa Zarębińska, a member of the Supervisory Board. The transaction, conducted on April 16, 2026, involved the purchase of 30 shares at a price of 33.9 PLN per share on the Warsaw Stock Exchange (XWAR). The notification was made in compliance with Article 19(1) of the MAR Regulation, and the full details are available in the attached report.

This development highlights the ongoing confidence in Syn2Bio S.A.'s strategic direction and its innovative projects, including the advanced phase-three clinical trials of its cardiotracer radiopharmaceutical for heart disease diagnosis.

Syn2Bio S.A. Acquires Founding Shares for Strategic Realignment

On April 22, 2026, Syn2Bio S.A., headquartered in Warsaw, finalized an agreement to acquire 200,000 Series A bearer shares, representing 2.29% of its share capital. The shares, valued at a nominal price of 0.50 PLN each, were purchased for a total of 100,000 PLN from shareholders Anna Szymańska and Cezary Kozanecki. This acquisition follows a preliminary agreement signed on February 18, 2026, and detailed in the company's prospectus approved by the Polish Financial Supervision Authority on March 12, 2026.

The acquired shares, originally technical founding shares, were issued to facilitate the division of Synektik S.A. and align the shareholder structure of Syn2Bio S.A. with that of Synektik S.A. The company plans to cancel these shares during the next general shareholders' meeting, ensuring a streamlined ownership structure.

Relevance: This strategic move underscores Syn2Bio S.A.'s commitment to optimizing its corporate structure as it advances its flagship cardiotracer radiopharmaceutical project, currently in phase-three clinical trials.

Syn2Bio S.A. Announces Extraordinary General Meeting to Address Key Corporate Decisions

Syn2Bio S.A., a leading Polish company specializing in innovative radiopharmaceuticals for heart disease diagnosis, has announced the convening of an Extraordinary General Meeting (EGM) scheduled for May 19, 2026, at its headquarters in Warsaw. The meeting will address critical corporate matters, including the voluntary redemption of 200,000 company shares, a reduction in share capital, and amendments to the company's statute. Additionally, the agenda includes the adoption of a new remuneration policy and the approval of the updated regulations for the Supervisory Board.

The share capital reduction aims to align the company's capital structure with its post-reorganization shareholder composition following the division of Synektik S.A. The new remuneration policy seeks to enhance corporate governance and align executive compensation with long-term business goals. The meeting will also finalize the rules governing the Supervisory Board, ensuring compliance with corporate governance standards.

Relevance to Syn2Bio S.A.: These decisions are pivotal for Syn2Bio S.A. as they directly impact its organizational structure and governance, which are crucial for the successful commercialization of its cardiotracer project currently in Phase III clinical trials.